[go: up one dir, main page]

AR059409A1 - Forma cristalina del succinato de 1-[2-(2-cloro-4-{[r-2-hidroxi-2-(8-hidroxi-2-oxo-1, 2-dihidroquinolin-5-il) etilamino] metil}-5- metoxifenilcarbamoil) etil] piperidin-4-il ester del acido bifenil-2-il-carbamico, una combinacion y una composicion farmaceutica que los contiene y el uso de la misma e - Google Patents

Forma cristalina del succinato de 1-[2-(2-cloro-4-{[r-2-hidroxi-2-(8-hidroxi-2-oxo-1, 2-dihidroquinolin-5-il) etilamino] metil}-5- metoxifenilcarbamoil) etil] piperidin-4-il ester del acido bifenil-2-il-carbamico, una combinacion y una composicion farmaceutica que los contiene y el uso de la misma e

Info

Publication number
AR059409A1
AR059409A1 ARP070100537A ARP070100537A AR059409A1 AR 059409 A1 AR059409 A1 AR 059409A1 AR P070100537 A ARP070100537 A AR P070100537A AR P070100537 A ARP070100537 A AR P070100537A AR 059409 A1 AR059409 A1 AR 059409A1
Authority
AR
Argentina
Prior art keywords
hidroxi
dihydroquinolin
piperidin
oxo
chloro
Prior art date
Application number
ARP070100537A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36119909&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR059409(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR059409A1 publication Critical patent/AR059409A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Una sal de succínico de 1-[2-(2-cloro-4-{[(R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilamino]metil}-5-etoxifenilcarbamoil)etil]piperidin-4-il éster del ácido bifenil-2-ilcarbámico o un solvato de la misma, para su uso en el tratamiento de trastornos pulmonares, composiciones farmacéuticas, combinaciones junto con un antiinflamatorio asteroideo que lo contienen y su uso en el tratamiento del asma y FPOC. Reivindicacion 28: Un procedimiento para reparar un compuesto de la reivindicacion 1 comprendiendo dicho procedimiento poner en contacto 1-[2-(2-cloro-4{[(R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2dihidroquinolin-5-il)etilamina]metil}-5-metoxifenilcarbamoil)-piperidin-4-il éster del ácido bifenil-2-ilcarbámico con ácido succínico Reivindicacion 29: Un procedimiento para preparar la Forma 1, comprendiendo dicho procedimiento las etapas: disolver la sal succinato en THF acuoso (al 10-18%) por ejemplo al 10-16%) a una temperatura comprendida en el intervalo de 18 a 23° C, por ejemplo a aproximadamente 20°C; anadir un primer volumen de un alcohol inferior, por ejemplo etanol o isopropanol en particular isopropanol, y calentar a 32-40°C; opcionalmente sembrando con la Forma 1; anadir un segundo volumen del alcohol inferior, por ejemplo durante varias horas, preferiblemente durante aproximadamente 12h; enfriar a una temperatura comprendida en el intervalo de 18 a 23°C, por ejemplo a aproximadamente 2°C; y recoger el producto cristalino.
ARP070100537A 2006-02-10 2007-02-08 Forma cristalina del succinato de 1-[2-(2-cloro-4-{[r-2-hidroxi-2-(8-hidroxi-2-oxo-1, 2-dihidroquinolin-5-il) etilamino] metil}-5- metoxifenilcarbamoil) etil] piperidin-4-il ester del acido bifenil-2-il-carbamico, una combinacion y una composicion farmaceutica que los contiene y el uso de la misma e AR059409A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0602778.3A GB0602778D0 (en) 2006-02-10 2006-02-10 Novel compound

Publications (1)

Publication Number Publication Date
AR059409A1 true AR059409A1 (es) 2008-04-09

Family

ID=36119909

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP070100537A AR059409A1 (es) 2006-02-10 2007-02-08 Forma cristalina del succinato de 1-[2-(2-cloro-4-{[r-2-hidroxi-2-(8-hidroxi-2-oxo-1, 2-dihidroquinolin-5-il) etilamino] metil}-5- metoxifenilcarbamoil) etil] piperidin-4-il ester del acido bifenil-2-il-carbamico, una combinacion y una composicion farmaceutica que los contiene y el uso de la misma e
ARP160101036A AR104288A2 (es) 2006-02-10 2016-04-15 Forma cristalina i de la sal del ácido succínico de 1-[2-(2-cloro-4-[(r)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilamino]metil-5-metoxifenilcarbamoil)etil]piperidin-4-il éster del ácido bifenil-2-ilcarbámico, composiciones, combinaciones y procedimiento para su preparación

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP160101036A AR104288A2 (es) 2006-02-10 2016-04-15 Forma cristalina i de la sal del ácido succínico de 1-[2-(2-cloro-4-[(r)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etilamino]metil-5-metoxifenilcarbamoil)etil]piperidin-4-il éster del ácido bifenil-2-ilcarbámico, composiciones, combinaciones y procedimiento para su preparación

Country Status (33)

Country Link
US (1) US7960551B2 (es)
EP (1) EP1981872B1 (es)
JP (1) JP5616021B2 (es)
KR (1) KR101488691B1 (es)
CN (1) CN101379057B (es)
AR (2) AR059409A1 (es)
AU (1) AU2007213767B2 (es)
BR (1) BRPI0707559B8 (es)
CA (1) CA2641769C (es)
CR (1) CR10227A (es)
CY (1) CY1119238T1 (es)
DK (1) DK1981872T3 (es)
EA (1) EA016580B1 (es)
ES (1) ES2640226T3 (es)
GB (1) GB0602778D0 (es)
HR (1) HRP20171304T1 (es)
HU (1) HUE034315T2 (es)
IL (1) IL193103A (es)
JO (1) JO3389B1 (es)
LT (1) LT1981872T (es)
MA (1) MA30273B1 (es)
MY (1) MY153656A (es)
NO (1) NO341343B1 (es)
NZ (1) NZ570242A (es)
PE (2) PE20071249A1 (es)
PL (1) PL1981872T3 (es)
PT (1) PT1981872T (es)
SG (1) SG169404A1 (es)
SI (1) SI1981872T1 (es)
TW (1) TWI401251B (es)
UA (1) UA100364C2 (es)
WO (1) WO2007090859A1 (es)
ZA (1) ZA200806782B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102395563B (zh) 2009-04-14 2015-05-20 葛兰素集团有限公司 联苯-2-基氨基甲酸酯的制备方法
AU2015234331B2 (en) * 2009-04-23 2017-08-03 Theravance Biopharma R&D Ip, Llc Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
MX2011011156A (es) * 2009-04-23 2011-11-04 Theravance Inc COMPUESTOS DIAMIDA QUE TIENE ACTIVIDAD COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS Y COMO AGONISTAS DE LOS RECEPTORES ANDRENERGICOS ß2.
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
AR083115A1 (es) 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
BR112014002593B1 (pt) * 2011-08-02 2022-11-29 Alfasigma S.p.A Composição farmacêutica de avidina oxidada apropriada para inalação e kits relacionados
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
ES2750523T3 (es) * 2012-12-18 2020-03-26 Almirall Sa Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
GB201500447D0 (en) * 2015-01-12 2015-02-25 Glaxosmithkline Ip Dev Ltd Novel Combination Product
CN106632257B (zh) * 2016-12-15 2019-02-12 上海市奉贤区中心医院 Gsk961081及其中间体的合成方法
WO2020047225A1 (en) 2018-08-30 2020-03-05 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4026897A (en) * 1974-01-31 1977-05-31 Otsuka Pharmaceutical Company 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives
DE3134590A1 (de) 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4894219A (en) * 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
DK443489D0 (da) 1989-09-08 1989-09-08 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
ES2141763T3 (es) 1992-03-31 2000-04-01 Glaxo Group Ltd Fenilcarbonatos y fenilureas sustituidos, su preparacion y su uso como antagonistas de 5-ht4.
CA2123728A1 (en) * 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
AU7545894A (en) 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
KR970701174A (ko) 1994-02-10 1997-03-17 오노다 마사요시 신규한 카바메이트 유도체 및 이의 의약 조성물(Novel carbamate derivative and medicinal composition containing the same)
AU7145996A (en) 1995-10-13 1997-04-30 Banyu Pharmaceutical Co., Ltd. Substituted heteroaromatic derivatives
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
JP2002508366A (ja) 1997-12-12 2002-03-19 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー キノリンピペラジンおよびキノリンピペリジン誘導体、それらの製造方法、ならびに複合的５−ｈｔ１ａ、５−ｈｔ１ｂおよび５−ｈｔ１ｄ受容体アンタゴニストとしてのそれらの用途
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
SG80041A1 (en) 1998-06-08 2001-04-17 Advanced Medicine Inc Muscarinic receptor antagonists
US6713651B1 (en) * 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
US6593497B1 (en) * 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
CA2392028C (en) 1999-12-07 2009-08-18 Theravance, Inc. Carbamate derivatives having muscarinic receptor antagonist activity
UA73543C2 (uk) 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
CZ20022332A3 (cs) * 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
KR20030031907A (ko) 2000-06-05 2003-04-23 알타나 파마 아게 β-2-아드레날린 수용체 작동물질로서 뿐만 아니라ＰＤＥ4-억제제로서 효과적인 화합물
HUP0303529A3 (en) 2000-12-22 2008-03-28 Almirall Ag New quinuclidine carbamate derivatives, process for their preparation and pharmaceutical compositions containing them and their use
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
WO2003042160A1 (en) * 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
ES2248767T3 (es) 2002-04-12 2006-03-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Medicamento que contiene beta-mimeticos y un nuevo anticolinergico.
AU2003239880A1 (en) * 2002-05-28 2003-12-12 Theravance, Inc. ALKOXY ARYL Beta2 ADRENERGIC RECEPTOR AGONISTS
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
UY27927A1 (es) 2002-08-06 2003-12-31 Glaxo Group Ltd Antagonistas del receptor muscarínico m3 de acetilcolina
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1615881A2 (en) 2003-04-01 2006-01-18 Theravance, Inc. Diarylmethyl and related compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
ES2329133T3 (es) * 2003-05-28 2009-11-23 Theravance, Inc. Compuestos azabicicloalcanicos como antagonistas de receptores de muscarinicos.
CA2543858C (en) * 2003-11-21 2014-04-15 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7320990B2 (en) * 2004-02-13 2008-01-22 Theravance, Inc. Crystalline form of a biphenyl compound
JP2008510015A (ja) * 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
WO2006023457A1 (en) * 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound

Also Published As

Publication number Publication date
BRPI0707559B8 (pt) 2021-05-25
EP1981872B1 (en) 2017-06-21
PL1981872T3 (pl) 2017-11-30
EP1981872A1 (en) 2008-10-22
US7960551B2 (en) 2011-06-14
PT1981872T (pt) 2017-09-13
KR20080114723A (ko) 2008-12-31
ES2640226T3 (es) 2017-11-02
CR10227A (es) 2008-10-29
SG169404A1 (en) 2011-03-30
HUE034315T2 (en) 2018-02-28
JO3389B1 (ar) 2019-03-13
TW200800948A (en) 2008-01-01
BRPI0707559B1 (pt) 2021-01-12
LT1981872T (lt) 2017-09-11
AU2007213767A1 (en) 2007-08-16
JP2009526018A (ja) 2009-07-16
WO2007090859A1 (en) 2007-08-16
HRP20171304T1 (hr) 2017-10-20
CA2641769A1 (en) 2007-08-16
AR104288A2 (es) 2017-07-12
UA100364C2 (xx) 2012-12-25
BRPI0707559A8 (pt) 2019-01-29
MA30273B1 (fr) 2009-03-02
EA016580B1 (ru) 2012-06-29
KR101488691B1 (ko) 2015-02-02
BRPI0707559A2 (pt) 2011-05-10
DK1981872T3 (en) 2017-09-11
IL193103A0 (en) 2009-02-11
NZ570242A (en) 2011-09-30
JP5616021B2 (ja) 2014-10-29
CN101379057B (zh) 2013-02-13
US20070281971A1 (en) 2007-12-06
NO341343B1 (no) 2017-10-16
PE20110120A1 (es) 2011-03-08
TWI401251B (zh) 2013-07-11
EA200801691A1 (ru) 2009-02-27
PE20071249A1 (es) 2008-01-16
SI1981872T1 (sl) 2017-10-30
IL193103A (en) 2013-06-27
MY153656A (en) 2015-03-13
CA2641769C (en) 2014-02-04
CN101379057A (zh) 2009-03-04
GB0602778D0 (en) 2006-03-22
ZA200806782B (en) 2009-10-28
NO20083425L (no) 2008-09-09
AU2007213767B2 (en) 2012-04-26
CY1119238T1 (el) 2018-02-14

Similar Documents

Publication Publication Date Title
AR059409A1 (es) Forma cristalina del succinato de 1-[2-(2-cloro-4-{[r-2-hidroxi-2-(8-hidroxi-2-oxo-1, 2-dihidroquinolin-5-il) etilamino] metil}-5- metoxifenilcarbamoil) etil] piperidin-4-il ester del acido bifenil-2-il-carbamico, una combinacion y una composicion farmaceutica que los contiene y el uso de la misma e
BRPI0514413C1 (pt) sal cristalino de composto de bifenil, sua composição farmacêutica, seus processos de preparação, processo de purificação, usos do referido sal e medicamento
PE20061142A1 (es) Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
BR112014009146A2 (pt) formulações de etanercepte estabilizadas com aminoácidos
WO2008131860A3 (de) Pyridoncarboxamide, diese enthaltende nutzpflanzenschützende mittel und verfahren zu ihrer herstellung und deren verwendung
MX2010009854A (es) Agente para liberacion de sustancia funcional.
WO2010018109A3 (en) Substituted aminotetralines
TH121482A (th) องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยอนุพันธ์ของควิโนลีน
CU23614B7 (es) Forma cristalina beta del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
EA200970942A1 (ru) Экстракт пажитника сенного (trigonella foenum-graecum)
WO2008101682A3 (en) Iminipyridine derivatives and their uses as microbiocides
NO20074580L (no) Anvendelse av proteiner som avemulgeringsmidler
BRPI0821748A2 (pt) método para produzir uma planta com rendimento aumentado, molécula isolada de ácido nucleico, construção de ácido nucleico, vetor, processo para produzir um polipeptídeo, polipeptídeo, anticorpo, núcleo de célula de planta, célula de planta, tecido de planta, material de propagação, semente, pólen, progênie, ou uma parte de planta, ou uma planta com rendimento aumento, processo para a indentificação de um composto, método para a produção de uma composição agrícola, composição, polipeptídeo ou molécula de ácido nucleico, uso dos ácidos nucléicos, e, método para a indentificação de uma planta com um rendimento aumentado
WO2006105306A3 (en) Compostions containing fatty acids and/or derivatives thereof and a low temperature stabilizer
PE20080186A1 (es) Derivados 4,6-disustituidos de 2-metoxi-6-etilamino-pirimidina como antagonistas del receptor de prostaglandina d2
SG10201407913UA (en) Crystalline freebase forms of a biphenyl compound
CO6351778A2 (es) Acidos naftilaceticos
CL2008003472A1 (es) Compuestos derivados de 5-[3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-ona, proceso para la preparacion de los mismos, compuestos intermediarios, composicion farmaceutica que comprende dicho compuesto; combinacion farmaceutica, y sus usos en el tratamiento de enfermedades inflamatorias.
WO2008140076A1 (ja) フォトレジスト剥離剤組成物
BRPI0712889A8 (pt) composto, processo para a preparação de um composto, composto intermediário, e, composição farmacêutica.
WO2008087654A3 (en) PIPERIDINES AS INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1
ITMI20061672A1 (it) Formulazioni di acido acetilsalicilico o suoi derivati in capsule molli,esibenti elevata stabilita'
WO2007025880A3 (en) Pyrazolone derivatives as 11-beta hsd1 inhibitors
CO6341474A2 (es) Formas solidas de (1r,2s,3r)-1-(2-isoxazol-3-il)-1h-imidazol-4-il) butano-1,2,3,4-tetraol y metodos para su uso
AR061299A1 (es) Sales de succionato de 6-metoxi -8- [4- (1-(5- fluor) -quinolin -8-il-piperidin-4-il) -piperazin-1-il] -quinolina y formas cristalinas de las mismas

Legal Events

Date Code Title Description
FC Refusal